# Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)

Source: https://onco.cc/trials/nct05348577/  
OnCo record `nct05348577` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Capivasertib, Docetaxel in prostate cancer, run by AstraZeneca, active and no longer recruiting.

## Summary

Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC) is a phase 3 interventional study registered as NCT05348577 by AstraZeneca, with 1035 participants enrolled, started 2022-03-25 and due to reach its primary completion in 2026-03-04. Interventions recorded: capivasertib, docetaxel, placebo. Conditions listed: Prostate Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05348577
- Phase: 3
- Setting: A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
- Sponsor: AstraZeneca
- Enrolled: 1035

## Sources

- ClinicalTrials.gov NCT05348577: https://clinicaltrials.gov/study/NCT05348577

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Capivasertib](https://onco.cc/drugs/capivasertib/), [Docetaxel](https://onco.cc/drugs/docetaxel/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct05348577.json